Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
•Genomic alterations in PDAC represent potential targeting opportunities to individualize therapy.•Attempts to target key somatic driver mutations in PDAC have been unsuccessful.•DNA-damage repair gene mutations confer vulnerability to platinum agents and PARP-inhibitors.•Microsatellite unstable PDA...
Gespeichert in:
| Veröffentlicht in: | Cancer treatment reviews Jg. 75; S. 27 - 38 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier Ltd
01.05.2019
|
| Schlagworte: | |
| ISSN: | 0305-7372, 1532-1967, 1532-1967 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | •Genomic alterations in PDAC represent potential targeting opportunities to individualize therapy.•Attempts to target key somatic driver mutations in PDAC have been unsuccessful.•DNA-damage repair gene mutations confer vulnerability to platinum agents and PARP-inhibitors.•Microsatellite unstable PDAC (1%) can benefit from checkpoint point inhibitor therapy.•The KRAS wild-type subset of PDAC (5%) is enriched for actionability, e.g., ALK, NTRK, NRG-1 fusions and others.
Pancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is growing interest in individualized therapy underpinned by somatic and germline genomic alterations.
A systematic review of data on therapies targeting somatic and germline alterations, and their downstream pathways in PDAC.
A systematic literature search was conducted using PRISMA guidelines to include relevant results published after January 1, 2008.
A total of 71 relevant studies were included. We identified 36 studies targeting the KRAS-pathway, the most common being with MEK-inhibitor therapy. Twenty-two studies were identified that evaluated platinum-based chemotherapy and PARP inhibitors in patients with deleterious mutations in DNA damage repair genes and have shown encouraging results. Immunotherapy has demonstrated activity in patients with mismatch repair deficiency/microsatellite instability.
Evidence from translational and clinical research presents an exciting platform for genomic targeted therapy in PDAC. Validity for targeting BRCA with platinum and PARP inhibitors and microsatellite instability with immune therapy has been established, nonetheless, evidence for targeting the common driver oncogenes is lacking and much work is needed. Of importance is identifying the subgroup of KRAS -wild type PDAC (approximately 5%) where there is enrichment for targetable opportunities. |
|---|---|
| AbstractList | Pancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is growing interest in individualized therapy underpinned by somatic and germline genomic alterations.CONTEXTPancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is growing interest in individualized therapy underpinned by somatic and germline genomic alterations.A systematic review of data on therapies targeting somatic and germline alterations, and their downstream pathways in PDAC.OBJECTIVEA systematic review of data on therapies targeting somatic and germline alterations, and their downstream pathways in PDAC.A systematic literature search was conducted using PRISMA guidelines to include relevant results published after January 1, 2008.METHODA systematic literature search was conducted using PRISMA guidelines to include relevant results published after January 1, 2008.A total of 71 relevant studies were included. We identified 36 studies targeting the KRAS-pathway, the most common being with MEK-inhibitor therapy. Twenty-two studies were identified that evaluated platinum-based chemotherapy and PARP inhibitors in patients with deleterious mutations in DNA damage repair genes and have shown encouraging results. Immunotherapy has demonstrated activity in patients with mismatch repair deficiency/microsatellite instability.RESULTSA total of 71 relevant studies were included. We identified 36 studies targeting the KRAS-pathway, the most common being with MEK-inhibitor therapy. Twenty-two studies were identified that evaluated platinum-based chemotherapy and PARP inhibitors in patients with deleterious mutations in DNA damage repair genes and have shown encouraging results. Immunotherapy has demonstrated activity in patients with mismatch repair deficiency/microsatellite instability.Evidence from translational and clinical research presents an exciting platform for genomic targeted therapy in PDAC. Validity for targeting BRCA with platinum and PARP inhibitors and microsatellite instability with immune therapy has been established, nonetheless, evidence for targeting the common driver oncogenes is lacking and much work is needed. Of importance is identifying the subgroup of KRAS -wild type PDAC (approximately 5%) where there is enrichment for targetable opportunities.CONCLUSIONEvidence from translational and clinical research presents an exciting platform for genomic targeted therapy in PDAC. Validity for targeting BRCA with platinum and PARP inhibitors and microsatellite instability with immune therapy has been established, nonetheless, evidence for targeting the common driver oncogenes is lacking and much work is needed. Of importance is identifying the subgroup of KRAS -wild type PDAC (approximately 5%) where there is enrichment for targetable opportunities. Pancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is growing interest in individualized therapy underpinned by somatic and germline genomic alterations. A systematic review of data on therapies targeting somatic and germline alterations, and their downstream pathways in PDAC. A systematic literature search was conducted using PRISMA guidelines to include relevant results published after January 1, 2008. A total of 71 relevant studies were included. We identified 36 studies targeting the KRAS-pathway, the most common being with MEK-inhibitor therapy. Twenty-two studies were identified that evaluated platinum-based chemotherapy and PARP inhibitors in patients with deleterious mutations in DNA damage repair genes and have shown encouraging results. Immunotherapy has demonstrated activity in patients with mismatch repair deficiency/microsatellite instability. Evidence from translational and clinical research presents an exciting platform for genomic targeted therapy in PDAC. Validity for targeting BRCA with platinum and PARP inhibitors and microsatellite instability with immune therapy has been established, nonetheless, evidence for targeting the common driver oncogenes is lacking and much work is needed. Of importance is identifying the subgroup of KRAS -wild type PDAC (approximately 5%) where there is enrichment for targetable opportunities. •Genomic alterations in PDAC represent potential targeting opportunities to individualize therapy.•Attempts to target key somatic driver mutations in PDAC have been unsuccessful.•DNA-damage repair gene mutations confer vulnerability to platinum agents and PARP-inhibitors.•Microsatellite unstable PDAC (1%) can benefit from checkpoint point inhibitor therapy.•The KRAS wild-type subset of PDAC (5%) is enriched for actionability, e.g., ALK, NTRK, NRG-1 fusions and others. Pancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is growing interest in individualized therapy underpinned by somatic and germline genomic alterations. A systematic review of data on therapies targeting somatic and germline alterations, and their downstream pathways in PDAC. A systematic literature search was conducted using PRISMA guidelines to include relevant results published after January 1, 2008. A total of 71 relevant studies were included. We identified 36 studies targeting the KRAS-pathway, the most common being with MEK-inhibitor therapy. Twenty-two studies were identified that evaluated platinum-based chemotherapy and PARP inhibitors in patients with deleterious mutations in DNA damage repair genes and have shown encouraging results. Immunotherapy has demonstrated activity in patients with mismatch repair deficiency/microsatellite instability. Evidence from translational and clinical research presents an exciting platform for genomic targeted therapy in PDAC. Validity for targeting BRCA with platinum and PARP inhibitors and microsatellite instability with immune therapy has been established, nonetheless, evidence for targeting the common driver oncogenes is lacking and much work is needed. Of importance is identifying the subgroup of KRAS -wild type PDAC (approximately 5%) where there is enrichment for targetable opportunities. |
| Author | O'Reilly, Eileen M. Park, Wungki Varghese, Anna M. Yu, Kenneth H. Singh, Ritu R. Goldberg, Johanna |
| AuthorAffiliation | 5. David M. Rubenstein Center for Pancreatic Research, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA 4. Weill Cornell Department of Medicine, Weill Cornell Medicine, New York, New York 10065, USA 2. MSK library, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA 1. Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai St. Luke’s and Mount Sinai West, New York, New York 10019, USA |
| AuthorAffiliation_xml | – name: 5. David M. Rubenstein Center for Pancreatic Research, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA – name: 1. Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai St. Luke’s and Mount Sinai West, New York, New York 10019, USA – name: 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA – name: 4. Weill Cornell Department of Medicine, Weill Cornell Medicine, New York, New York 10065, USA – name: 2. MSK library, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA |
| Author_xml | – sequence: 1 givenname: Ritu R. surname: Singh fullname: Singh, Ritu R. email: ritu.singh@mountsinai.org organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai St. Luke’s and Mount Sinai West, New York, NY 10019, USA – sequence: 2 givenname: Johanna surname: Goldberg fullname: Goldberg, Johanna email: goldbejb@mskcc.org organization: MSK Library, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA – sequence: 3 givenname: Anna M. surname: Varghese fullname: Varghese, Anna M. organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA – sequence: 4 givenname: Kenneth H. surname: Yu fullname: Yu, Kenneth H. organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA – sequence: 5 givenname: Wungki orcidid: 0000-0002-8006-3102 surname: Park fullname: Park, Wungki organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA – sequence: 6 givenname: Eileen M. surname: O'Reilly fullname: O'Reilly, Eileen M. email: oreillye@mskcc.org organization: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30927677$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktvEzEUhS1URB_wB1igWbJJ8CNjz1QIqaqgIFViA2vr9vqmcZjYg-0kSn89DmkRdFFWluzznSOd41N2FGIgxl4LPhVc6HfLKZa0mUou-ilXU87VM3YiWiUnotfmiJ1wxduJUUYes9Ocl5zzXun-BTtWvJdGG3PCtlcU4spjM6Y494MPt40PzQgBE0Gp926NBYYGXNUhJPRVDg0E10CVlcUWdk2JW0guN2VBCcZddXB-490aBn9XTWI4by6ajHHc2yfaeNq-ZM_nMGR6dX-ese-fPn67_Dy5_nr15fLieoKtkWXSkzNCAaceetGJuZ7dCBQkJJLu0EilnVCkDSCBMiC4nCtsW-gNUudEp87Yh4PvuL5ZkUMKJcFgx-RXkHY2grf_vgS_sLdxY3XLZ61W1eDtvUGKP9eUi135jDQMECius5WSc6O7js-q9M3fWX9CHtqugu4gwBRzTjS36Mvvgmq0H6zgdj-sXdr9sHY_rOXK1mErKh-hD-5PQu8PENWGa-vJZvQUkJxPhMW66J_Gzx_hWD-IRxh-0O5_8C8I59QZ |
| CitedBy_id | crossref_primary_10_1016_j_clinre_2020_101589 crossref_primary_10_1186_s12885_023_10675_y crossref_primary_10_3390_ijms21114091 crossref_primary_10_1016_j_soc_2021_06_008 crossref_primary_10_1016_j_pan_2020_01_013 crossref_primary_10_3390_cancers12123866 crossref_primary_10_1186_s13046_022_02469_0 crossref_primary_10_3390_cancers17121899 crossref_primary_10_4251_wjgo_v11_i11_933 crossref_primary_10_1007_s40265_020_01304_0 crossref_primary_10_1016_j_pec_2020_07_010 crossref_primary_10_1136_jclinpath_2021_207781 crossref_primary_10_3389_fcell_2022_819724 crossref_primary_10_3390_pharmaceutics13050653 crossref_primary_10_1007_s00262_021_03019_x crossref_primary_10_1186_s13046_020_01732_6 crossref_primary_10_1007_s11938_022_00386_x crossref_primary_10_1097_MPA_0000000000001461 crossref_primary_10_3390_molecules27041289 crossref_primary_10_1002_adbi_202400720 crossref_primary_10_2217_imt_2020_0344 crossref_primary_10_1002_mco2_216 crossref_primary_10_1097_MPA_0000000000001804 crossref_primary_10_1002_cncr_33038 crossref_primary_10_1093_annonc_mdz385 |
| Cites_doi | 10.1200/JCO.2006.07.9525 10.1158/1078-0432.CCR-14-1814 10.18632/oncotarget.4216 10.1038/ncomms7744 10.1016/S0959-8049(16)32624-7 10.1056/NEJMoa1714448 10.1007/s10637-012-9818-6 10.1016/j.ctrv.2017.08.007 10.1016/j.ccell.2017.07.007 10.1158/1078-0432.CCR-17-0899 10.1093/annonc/mdr617 10.1093/annonc/mdx369.120 10.6004/jnccn.2017.0058 10.1093/annonc/mdx369.115 10.1158/1078-0432.CCR-15-0979 10.1038/s41591-018-0111-x 10.1056/NEJMoa1304369 10.1097/MPA.0000000000000640 10.1038/nature18621 10.1634/theoncologist.10-5-345 10.1038/bjc.2014.418 10.1002/cncr.31218 10.1158/1078-0432.CCR-18-0531 10.1056/NEJMoa1011923 10.1634/theoncologist.2011-0185 10.1056/NEJMoa1200690 10.1200/jco.2011.29.4_suppl.268 10.1007/s10637-011-9687-4 10.1080/07357900801918611 10.1016/j.jmoldx.2014.12.006 10.1158/1538-7445.PANCA2014-B102 10.1038/mt.2016.66 10.1159/000330194 10.1371/journal.pmed.1000097 10.1158/1078-0432.CCR-15-0124 10.18632/oncotarget.14901 10.1056/NEJMoa1500596 10.1016/j.ejca.2014.04.024 10.1158/1078-0432.CCR-18-1472 10.1200/JCO.2017.35.4_suppl.792 10.1126/scisignal.2005516 10.3390/cancers10060160 10.1200/JCO.2019.37.4_suppl.188 10.1038/nature12796 10.1016/S1470-2045(15)00188-6 10.1158/1078-0432.CCR-15-0426 10.1016/S0140-6736(15)00986-1 10.1200/JCO.2018.36.4_suppl.521 10.1093/annonc/mdx376.018 10.1158/1078-0432.CCR-17-2994 10.1093/annonc/mdx369.053 10.1038/nature14169 10.1001/jamaoncol.2016.5383 10.1158/1078-0432.CCR-12-3020 10.1200/JCO.2014.59.7401 10.1016/j.ejca.2017.11.004 10.1016/S0923-7534(19)66467-7 10.1007/s11523-016-0469-y 10.1158/2159-8290.CD-18-0036 10.1002/cncr.29664 10.18632/oncotarget.4183 10.1001/jama.2013.279201 10.1200/PO.17.00316 10.1016/j.ijrobp.2013.06.2039 10.1200/JCO.2017.35.4_suppl.250 10.18632/oncotarget.17237 10.3390/ijms18050909 10.3163/1536-5050.104.3.014 10.18632/oncotarget.24865 10.3892/or.2013.2556 10.1002/ijc.31603 10.1038/bjc.2017.19 10.1093/jnci/djv253 10.1001/jamaoncol.2017.3420 10.1016/S1470-2045(12)70270-X 10.1200/JCO.2009.25.7550 10.1158/1078-0432.CCR-13-3271 10.1016/j.prp.2016.06.001 10.1158/1535-7163.TARG-11-A88 10.1093/annonc/mdv264 10.1097/CAD.0000000000000178 10.1016/j.ctrv.2016.10.009 10.1053/j.gastro.2013.01.078 10.1002/ijc.25449 10.1158/0008-5472.CAN-14-0155 10.1200/JCO.2010.33.8038 10.1158/1538-7445.AM2018-4603 10.1200/JCO.2004.10.112 10.1158/2159-8290.CD-15-1105 10.1200/jco.2015.33.3_suppl.357 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.ctrv.2019.03.003 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1967 |
| EndPage | 38 |
| ExternalDocumentID | PMC6504563 30927677 10_1016_j_ctrv_2019_03_003 S0305737219300519 |
| Genre | Journal Article Scoping Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 4.4 457 4CK 4G. 4H- 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W J5H KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WOW WUQ Z5R ZGI ~G- ~HD AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW LCYCR RIG ZA5 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c572t-9ed713a0e9a9181f64b1c1e12ce68c7236d13e67acea37a102f3c55a97ce8d183 |
| ISICitedReferencesCount | 29 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000467510600004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0305-7372 1532-1967 |
| IngestDate | Tue Sep 30 15:33:06 EDT 2025 Thu Oct 02 11:05:52 EDT 2025 Mon Jul 21 05:26:47 EDT 2025 Tue Nov 18 22:34:37 EST 2025 Sat Nov 29 07:25:53 EST 2025 Fri Feb 23 02:29:29 EST 2024 Tue Oct 14 19:30:24 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Somatic mutation Mismatch repair (MMR) DNA damage repair Pancreatic ductal adenocarcinoma (PDAC) Genomic alteration (GA) Germline mutation Microsatellite instability |
| Language | English |
| License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c572t-9ed713a0e9a9181f64b1c1e12ce68c7236d13e67acea37a102f3c55a97ce8d183 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-8006-3102 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/6504563 |
| PMID | 30927677 |
| PQID | 2200768804 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6504563 proquest_miscellaneous_2200768804 pubmed_primary_30927677 crossref_citationtrail_10_1016_j_ctrv_2019_03_003 crossref_primary_10_1016_j_ctrv_2019_03_003 elsevier_sciencedirect_doi_10_1016_j_ctrv_2019_03_003 elsevier_clinicalkey_doi_10_1016_j_ctrv_2019_03_003 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-01 |
| PublicationDateYYYYMMDD | 2019-05-01 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Cancer treatment reviews |
| PublicationTitleAlternate | Cancer Treat Rev |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Chen, LaMarche, Chan, Fekkes, Garcia-Fortanet, Acker (b0500) 2016; 535 Cheng, Mitchell, Zehir, Shah, Benayed, Syed (b0350) 2015; 17 Institute NC. Cancer stat facts: pancreatic cancer. April 2018 ed: surveillance, Epidemiology and End Results Program; 2018. Noonan, Farren, Geyer, Huang, Tahiri, Ahn (b0255) 2016; 24 Varga, Soria, Hollebecque, LoRusso, Vaishampayan, Okrah (b0260) 2016; 69 Bachet, Marechal, Demetter, Bonnetain, Couvelard, Svrcek (b0300) 2012; 23 Moore, Goldstein, Hamm, Figer, Hecht, Gallinger (b0085) 2007; 25 Infante, Fecher, Falchook, Nallapareddy, Gordon, Becerra (b0145) 2012; 13 Sehdev, Gbolahan, Hancock, Stanley, Shahda, Wan (b0375) 2018; 24 Fountzilas, Bobos, Kalogera-Fountzila, Xiros, Murray, Linardou (b0220) 2008; 26 Eriksen, Gladhaug, Rosseland, Risberg Handeland, Buanes (b0170) 2017; 28 Kundranda, Donald Peter, Kramer, Ai, Tan, Kilmant (b0140) 2015; 33 Le Tourneau, Delord, Gonçalves, Gavoille, Dubot, Isambert (b0135) 2015; 16 Vyas, Leung, Ledbetter, Kaley, Rodriguez, Garcon (b0370) 2015; 26 Paulson, Tran Cao, Tempero, Lowy (b0025) 2013; 144 Drilon, Laetsch, Kummar, DuBois, Lassen, Demetri (b0290) 2018; 378 Le, Uram, Wang, Bartlett, Kemberling, Eyring (b0425) 2015; 372 Egeli, Tezcan, Cecener, Tunca, Demirdogen Sevinc, Kaya (b0345) 2016; 45 Puleo F, Nicolle R, Blum Y, Cros J, Elarouci N, Franchimont D, et al. Clinical application and potential usefulness of targeted next-generation sequencing on resected pancreatic ductal adenocarcinoma; 2018. p. 78. Wang, Wu, Yeh, Shyr, Wu, Kuo (b0240) 2015; 6 Kullmann, Hartmann, Stohr, Messmann, Dollinger, Trojan (b0230) 2011; 81 . Le, Uram, Wang, Bartlett, Kemberling, Eyring (b9000) 2015; 372 Mai, Lito (b0495) 2018; 24 Shroff, Hendifar, McWilliams, Geva, Epelbaum, Rolfe (b0405) 2018 Singhi, Ali, Greenbowe, Ross, Nguyen, Nikiforova (b0275) 2016; 96 Sinn, Budczies, Damm, Lohneis, Schmuck, Treue (b0330) 2017; 28 Qian, Rubinson, Nowak, Morales-Oyarvide, Dunne, Kozak (b0080) 2018; 4 Weden, Klemp, Gladhaug, Moller, Eriksen, Gaudernack (b0180) 2011; 128 Blair, Groot, Gemenetzis, Wei, Cameron, Weiss (b0400) 2018; 226 Van Cutsem, Hidalgo, Canon, Macarulla, Bazin, Poddubskaya (b0110) 2018 Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018. Golan, Sella, O'Reilly, Katz, Epelbaum, Kelsen (b0390) 2017; 116 Adjei, Richards, El-Khoueiry, Becerra, Stephenson, Leffingwell (b0150) 2011; 10 O'Neil, Scott, Ma, Cohen, Leichman, Aisner (b0205) 2015; 26 based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Kondo, Kanai, Kou, Sakuma, Mochizuki, Kamada (b0010) 2018; 9 Jardim, Groves, Breitfeld, Kurzrock (b0435) 2017; 52 Shin, Kim, Hwang, Lee, Song, Jun (b0310) 2017; 8 Oettle, Neuhaus, Hochhaus (b0315) 2013; 310 Striefler, Sinn, Pelzer, Juhling, Wislocka, Bahra (b0320) 2016; 212 Bodoky, Timcheva, Spigel, La Stella, Ciuleanu, Pover (b0120) 2012; 30 Lowery, Kelsen, Capanu, Smith, Lee, Stadler (b0050) 2018; 89 Mahalingam, Goel, Aparo, Patel Arora, Noronha, Tran (b0250) 2018; 10 Van Cutsem, van de Velde, Karasek, Oettle, Vervenne, Szawlowski (b0195) 2004; 22 Chung, McDonough, Philip, Cardin, Wang-Gillam, Hui (b0130) 2017; 3 Golan, Khvalevsky, Hubert, Gabai, Hen, Segal (b0200) 2015; 6 Golan, Kanji, Epelbaum, Devaud, Dagan, Holter (b0395) 2014; 111 Bramer, Giustini, de Jonge, Holland, Bekhuis (b0100) 2016; 104 Dueland, Valle, Bell, Faluyi, Staiger, Gjertsen (b0165) 2017; 28 Salo-Mullen, O'Reilly, Kelsen, Ashraf, Lowery, Yu (b0460) 2015; 121 Ko, Bekaii-Saab, Van Ziffle, Mirzoeva, Joseph, Talasaz (b0125) 2016; 22 Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. 2018;36:521. Lucas, Shakya, Lipsyc, Mitchel, Kumar, Hwang (b0415) 2013; 19 Lowery, Stadler, Ludwig, Salo-Mullen, D'Adamo, Allen (b0385) 2011; 29 Taube, Klein, Brahmer, Xu, Pan, Kim (b0480) 2014 Aung, Fischer, Denroche, Jang, Dodd, Creighton (b0335) 2018; 24 Domchek SM, McWilliams R, Hendifar A, Shroff RT, Leichman L, Epelbaum R, et al. A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. In: Cancer research conference: AACR special conference on pancreatic cancer: innovations in research and treatment 2014 New Orleans, LA United States conference start: 20140518 conference end: 20140521 Conference publication: (varpagings); 2015. p. 75. 10.1158/1538- Yutani, Komatsu, Yoshitomi, Matsueda, Yonemoto, Mine (b0185) 2013; 30 Assenat, Mineur, Mollevi, Lombard-Bohas, Mazard, Samalin (b0210) 2015; 18 Infante, Somer, Park, Li, Scheulen, Kasubhai (b0105) 2014; 50 Chiramel, Backen, Pihlak, Lamarca, Frizziero, Tariq (b0215) 2017; 18 Kim, Foster, Salim, Flynn, Moore, Zon (b0225) 2011; 29 Singhi, Ali, Lacy, Hendifar, Nguyen, Koo (b0280) 2017; 15 Weekes, Lockhart, LoRusso, Murray, Park, Tagen (b0265) 2017 O'Kane, Borgida, Dodd, Aung, Holter, Knox (b0380) 2017; 28 Belmont, Jiang, McKee, Xie, Isaacson, Baryla (b0505) 2014; 7 Rahib, Smith, Aizenberg, Rosenzweig, Fleshman, Matrisian (b0015) 2014; 74 Waddell, Pajic, Patch, Chang, Kassahn, Bailey (b0365) 2015; 518 Chantrill, Nagrial, Watson, Johns, Martyn-Smith, Simpson (b0465) 2015; 21 Laheru, Shah, Rajeshkumar, McAllister, Taylor, Goldsweig (b0190) 2012; 30 Heining, Horak, Uhrig, Codo, Klink, Hutter (b0270) 2018 Kondo, Kanai, Kou, Sakuma, Mochizuki, Kamada (b0360) 2017; 35 Hu, Varghese, Shia, Zervoudakis, Lowery, Yu (b0420) 2017 Ostrem, Peters, Sos, Wells, Shokat (b0485) 2013; 503 Pishvaian, Bender, Halverson, Rahib, Hendifar, Mikhail (b0340) 2018; 24 Cavalieri, Swanson, Whisenant, Weis, Gilcrease, Stenehjem (b0430) 2017; 35 O'Kane G, Fischer S, Denroche R, Ho Jang G, Zhang A, Dodd A, et al. Integrative molecular profiling and response to chemotherapy on the COMPASS trial; 2019. Holter, Borgida, Dodd, Grant, Semotiuk, Hedley (b0455) 2015; 33 Chiaravalli, Reni, O'Reilly (b0065) 2017; 60 Yarchoan, Myzak, Johnson, De Jesus-Acosta, Le, Jaffee (b0060) 2017; 8 Yang, Lee, Guo, Kuo, Tien, Kuo (b0325) 2017; 12 O'Reilly, Lee, Lowery, Capanu, Stadler, Moore (b0055) 2018; 124 Topalian, Hodi, Brahmer, Gettinger, Smith, McDermott (b0475) 2012; 366 Lowery, Jordan, Basturk, Ptashkin, Zehir, Berger (b0355) 2017; 23 Bedard, Tabernero, Janku, Aw, Paz-Ares, Vansteenkiste (b0155) 2015; 21 Richards, Muscarella, Bekaii-Saab, Wilfong, Rosemurgy, Ross (b0175) 2012; 23 Philip, Benedetti, Corless, Wong, O'Reilly, Flynn (b0235) 2010; 28 Seruga, Ocana, Amir, Tannock (b0440) 2015; 21 Von Hoff, Ervin, Arena, Chiorean, Infante, Moore (b0030) 2013; 369 Weekes, Lockhard, Lorusso, Murray, Park, Tagen (b0160) 2017 Witkiewicz, McMillan, Balaji, Baek, Lin, Mansour (b0470) 2015; 6 Patricelli, Janes, Li, Hansen, Peters, Kessler (b0490) 2016; 6 Perez-Soler, Delord, Halpern, Kelly, Krueger, Sureda (b0245) 2005; 10 Herman, Fan, Wild, Wood, Blackford, Donehower (b0305) 2013; 87 Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185-203.e13. Doi: 10.1016/j.ccell.2017.07.007. Van Laethem, Riess, Jassem, Haas, Martens, Weekes (b0115) 2017; 12 Crane, Varadhachary, Yordy, Staerkel, Javle, Safran (b0295) 2011; 29 Jardim, Schwaederle, Wei, Lee, Hong, Eggermont (b0445) 2015; 107 Wang-Gillam, Li, Bodoky, Dean, Shan, Jameson (b0035) 2016; 387 Moher, Liberati, Tetzlaff, Altman (b0095) 2009; 6 Conroy, Desseigne, Ychou, Bouché, Guimbaud, Bécouarn (b0020) 2011; 364 Lowery, Kelsen, Stadler, Yu, Janjigian, Ludwig (b0410) 2011; 16 NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2018; Version 1; 2019. Shin (10.1016/j.ctrv.2019.03.003_b0310) 2017; 8 Taube (10.1016/j.ctrv.2019.03.003_b0480) 2014 Aung (10.1016/j.ctrv.2019.03.003_b0335) 2018; 24 Ko (10.1016/j.ctrv.2019.03.003_b0125) 2016; 22 Van Cutsem (10.1016/j.ctrv.2019.03.003_b0110) 2018 Fountzilas (10.1016/j.ctrv.2019.03.003_b0220) 2008; 26 Philip (10.1016/j.ctrv.2019.03.003_b0235) 2010; 28 Weden (10.1016/j.ctrv.2019.03.003_b0180) 2011; 128 Hu (10.1016/j.ctrv.2019.03.003_b0420) 2017 Dueland (10.1016/j.ctrv.2019.03.003_b0165) 2017; 28 Rahib (10.1016/j.ctrv.2019.03.003_b0015) 2014; 74 Shroff (10.1016/j.ctrv.2019.03.003_b0405) 2018 10.1016/j.ctrv.2019.03.003_b0285 10.1016/j.ctrv.2019.03.003_b0045 Conroy (10.1016/j.ctrv.2019.03.003_b0020) 2011; 364 10.1016/j.ctrv.2019.03.003_b0040 Weekes (10.1016/j.ctrv.2019.03.003_b0265) 2017 Singhi (10.1016/j.ctrv.2019.03.003_b0280) 2017; 15 Van Laethem (10.1016/j.ctrv.2019.03.003_b0115) 2017; 12 Kondo (10.1016/j.ctrv.2019.03.003_b0360) 2017; 35 Yang (10.1016/j.ctrv.2019.03.003_b0325) 2017; 12 Bodoky (10.1016/j.ctrv.2019.03.003_b0120) 2012; 30 Yutani (10.1016/j.ctrv.2019.03.003_b0185) 2013; 30 Le Tourneau (10.1016/j.ctrv.2019.03.003_b0135) 2015; 16 Kondo (10.1016/j.ctrv.2019.03.003_b0010) 2018; 9 Bramer (10.1016/j.ctrv.2019.03.003_b0100) 2016; 104 Holter (10.1016/j.ctrv.2019.03.003_b0455) 2015; 33 Witkiewicz (10.1016/j.ctrv.2019.03.003_b0470) 2015; 6 10.1016/j.ctrv.2019.03.003_b0450 Lowery (10.1016/j.ctrv.2019.03.003_b0410) 2011; 16 Kim (10.1016/j.ctrv.2019.03.003_b0225) 2011; 29 Pishvaian (10.1016/j.ctrv.2019.03.003_b0340) 2018; 24 Seruga (10.1016/j.ctrv.2019.03.003_b0440) 2015; 21 Adjei (10.1016/j.ctrv.2019.03.003_b0150) 2011; 10 Assenat (10.1016/j.ctrv.2019.03.003_b0210) 2015; 18 Golan (10.1016/j.ctrv.2019.03.003_b0200) 2015; 6 Lowery (10.1016/j.ctrv.2019.03.003_b0355) 2017; 23 Eriksen (10.1016/j.ctrv.2019.03.003_b0170) 2017; 28 Chiramel (10.1016/j.ctrv.2019.03.003_b0215) 2017; 18 Drilon (10.1016/j.ctrv.2019.03.003_b0290) 2018; 378 Golan (10.1016/j.ctrv.2019.03.003_b0390) 2017; 116 Striefler (10.1016/j.ctrv.2019.03.003_b0320) 2016; 212 Jardim (10.1016/j.ctrv.2019.03.003_b0435) 2017; 52 Belmont (10.1016/j.ctrv.2019.03.003_b0505) 2014; 7 Le (10.1016/j.ctrv.2019.03.003_b0425) 2015; 372 Lowery (10.1016/j.ctrv.2019.03.003_b0385) 2011; 29 Kundranda (10.1016/j.ctrv.2019.03.003_b0140) 2015; 33 10.1016/j.ctrv.2019.03.003_b0510 10.1016/j.ctrv.2019.03.003_b0075 Qian (10.1016/j.ctrv.2019.03.003_b0080) 2018; 4 Lucas (10.1016/j.ctrv.2019.03.003_b0415) 2013; 19 Ostrem (10.1016/j.ctrv.2019.03.003_b0485) 2013; 503 Patricelli (10.1016/j.ctrv.2019.03.003_b0490) 2016; 6 10.1016/j.ctrv.2019.03.003_b0070 Cavalieri (10.1016/j.ctrv.2019.03.003_b0430) 2017; 35 O'Reilly (10.1016/j.ctrv.2019.03.003_b0055) 2018; 124 Sinn (10.1016/j.ctrv.2019.03.003_b0330) 2017; 28 Moher (10.1016/j.ctrv.2019.03.003_b0095) 2009; 6 Blair (10.1016/j.ctrv.2019.03.003_b0400) 2018; 226 Cheng (10.1016/j.ctrv.2019.03.003_b0350) 2015; 17 Topalian (10.1016/j.ctrv.2019.03.003_b0475) 2012; 366 10.1016/j.ctrv.2019.03.003_b0005 Mai (10.1016/j.ctrv.2019.03.003_b0495) 2018; 24 Perez-Soler (10.1016/j.ctrv.2019.03.003_b0245) 2005; 10 Vyas (10.1016/j.ctrv.2019.03.003_b0370) 2015; 26 Weekes (10.1016/j.ctrv.2019.03.003_b0160) 2017 Varga (10.1016/j.ctrv.2019.03.003_b0260) 2016; 69 Van Cutsem (10.1016/j.ctrv.2019.03.003_b0195) 2004; 22 Wang (10.1016/j.ctrv.2019.03.003_b0240) 2015; 6 Oettle (10.1016/j.ctrv.2019.03.003_b0315) 2013; 310 Lowery (10.1016/j.ctrv.2019.03.003_b0050) 2018; 89 Infante (10.1016/j.ctrv.2019.03.003_b0145) 2012; 13 Chen (10.1016/j.ctrv.2019.03.003_b0500) 2016; 535 Mahalingam (10.1016/j.ctrv.2019.03.003_b0250) 2018; 10 Sehdev (10.1016/j.ctrv.2019.03.003_b0375) 2018; 24 Wang-Gillam (10.1016/j.ctrv.2019.03.003_b0035) 2016; 387 Singhi (10.1016/j.ctrv.2019.03.003_b0275) 2016; 96 Chung (10.1016/j.ctrv.2019.03.003_b0130) 2017; 3 Egeli (10.1016/j.ctrv.2019.03.003_b0345) 2016; 45 Von Hoff (10.1016/j.ctrv.2019.03.003_b0030) 2013; 369 O'Neil (10.1016/j.ctrv.2019.03.003_b0205) 2015; 26 Chantrill (10.1016/j.ctrv.2019.03.003_b0465) 2015; 21 Jardim (10.1016/j.ctrv.2019.03.003_b0445) 2015; 107 Richards (10.1016/j.ctrv.2019.03.003_b0175) 2012; 23 Le (10.1016/j.ctrv.2019.03.003_b9000) 2015; 372 Chiaravalli (10.1016/j.ctrv.2019.03.003_b0065) 2017; 60 Kullmann (10.1016/j.ctrv.2019.03.003_b0230) 2011; 81 Salo-Mullen (10.1016/j.ctrv.2019.03.003_b0460) 2015; 121 Bedard (10.1016/j.ctrv.2019.03.003_b0155) 2015; 21 Noonan (10.1016/j.ctrv.2019.03.003_b0255) 2016; 24 Yarchoan (10.1016/j.ctrv.2019.03.003_b0060) 2017; 8 Laheru (10.1016/j.ctrv.2019.03.003_b0190) 2012; 30 Bachet (10.1016/j.ctrv.2019.03.003_b0300) 2012; 23 Moore (10.1016/j.ctrv.2019.03.003_b0085) 2007; 25 Herman (10.1016/j.ctrv.2019.03.003_b0305) 2013; 87 Infante (10.1016/j.ctrv.2019.03.003_b0105) 2014; 50 Waddell (10.1016/j.ctrv.2019.03.003_b0365) 2015; 518 Paulson (10.1016/j.ctrv.2019.03.003_b0025) 2013; 144 Heining (10.1016/j.ctrv.2019.03.003_b0270) 2018 O'Kane (10.1016/j.ctrv.2019.03.003_b0380) 2017; 28 Golan (10.1016/j.ctrv.2019.03.003_b0395) 2014; 111 Crane (10.1016/j.ctrv.2019.03.003_b0295) 2011; 29 |
| References_xml | – volume: 364 start-page: 1817 year: 2011 end-page: 1825 ident: b0020 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med – volume: 23 start-page: 2327 year: 2012 end-page: 2335 ident: b0300 article-title: Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma publication-title: Ann Oncol – volume: 87 start-page: 458 year: 2013 end-page: 459 ident: b0305 article-title: Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma publication-title: Int J Radiat Oncol Biol Phys – volume: 50 start-page: 2072 year: 2014 end-page: 2081 ident: b0105 article-title: A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas publication-title: Eur J Cancer – volume: 81 start-page: 3 year: 2011 end-page: 8 ident: b0230 article-title: KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy publication-title: Oncology – volume: 8 start-page: 44073 year: 2017 end-page: 44081 ident: b0060 article-title: Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer publication-title: Oncotarget – volume: 22 start-page: 61 year: 2016 end-page: 68 ident: b0125 article-title: A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma publication-title: Clin Cancer Res – year: 2017 ident: b0160 article-title: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors publication-title: AACR annual meeting – volume: 13 start-page: 773 year: 2012 end-page: 781 ident: b0145 article-title: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial publication-title: Lancet Oncol – volume: 16 start-page: 1397 year: 2011 end-page: 1402 ident: b0410 article-title: An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions publication-title: Oncologist – volume: 10 year: 2011 ident: b0150 article-title: pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients publication-title: Mol Cancer Ther – volume: 24 start-page: 5018 year: 2018 end-page: 5027 ident: b0340 article-title: Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative publication-title: Clin Cancer Res – year: 2018 ident: b0110 article-title: Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer publication-title: Int J Cancer – volume: 29 year: 2011 ident: b0225 article-title: Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma publication-title: J Clin Oncol – volume: 25 start-page: 1960 year: 2007 end-page: 1966 ident: b0085 article-title: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group publication-title: J Clin Oncol – volume: 16 start-page: 1324 year: 2015 end-page: 1334 ident: b0135 article-title: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial publication-title: Lancet Oncol – volume: 9 start-page: 19817 year: 2018 end-page: 19825 ident: b0010 article-title: Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer publication-title: Oncotarget – volume: 372 start-page: 2509 year: 2015 end-page: 2520 ident: b0425 article-title: PD-1 blockade in tumors with mismatch-repair deficiency publication-title: N Engl J Med – volume: 35 start-page: 792- year: 2017 ident: b0430 article-title: Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): a single institution experience publication-title: J Clin Oncol – reference: Domchek SM, McWilliams R, Hendifar A, Shroff RT, Leichman L, Epelbaum R, et al. A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. In: Cancer research conference: AACR special conference on pancreatic cancer: innovations in research and treatment 2014 New Orleans, LA United States conference start: 20140518 conference end: 20140521 Conference publication: (varpagings); 2015. p. 75. 10.1158/1538- – volume: 26 start-page: 224 year: 2015 end-page: 226 ident: b0370 article-title: Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation publication-title: Anticancer Drugs – reference: O'Kane G, Fischer S, Denroche R, Ho Jang G, Zhang A, Dodd A, et al. Integrative molecular profiling and response to chemotherapy on the COMPASS trial; 2019. – volume: 26 start-page: 1923 year: 2015 end-page: 1929 ident: b0205 article-title: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer publication-title: Ann Oncol – volume: 29 year: 2011 ident: b0385 article-title: Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation publication-title: J Clin Oncol – volume: 74 start-page: 2913 year: 2014 end-page: 2921 ident: b0015 article-title: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States publication-title: Cancer Res – volume: 12 start-page: 97 year: 2017 end-page: 109 ident: b0115 article-title: Phase I/II study of refametinib (BAY 86–9766) in combination with gemcitabine in advanced pancreatic cancer publication-title: Target Oncol – volume: 28 start-page: v251 year: 2017 ident: b0330 article-title: TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: results from the CONKO-001 study publication-title: Ann Oncol – volume: 10 year: 2018 ident: b0250 article-title: Phase II study of pelareorep (REOLYSIN((R))) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma publication-title: Cancers (Basel) – reference: Institute NC. Cancer stat facts: pancreatic cancer. April 2018 ed: surveillance, Epidemiology and End Results Program; 2018. – volume: 503 start-page: 548 year: 2013 end-page: 551 ident: b0485 article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature – volume: 518 start-page: 495 year: 2015 end-page: 501 ident: b0365 article-title: Whole genomes redefine the mutational landscape of pancreatic cancer publication-title: Nature – volume: 6 start-page: 18162 year: 2015 end-page: 18173 ident: b0240 article-title: Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial publication-title: Oncotarget – volume: 6 start-page: 6744 year: 2015 ident: b0470 article-title: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets publication-title: Nat Commun – volume: 310 start-page: 1473 year: 2013 end-page: 1481 ident: b0315 article-title: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the conko-001 randomized trial publication-title: JAMA – volume: 3 start-page: 516 year: 2017 end-page: 522 ident: b0130 article-title: Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial publication-title: JAMA Oncol – volume: 18 year: 2015 ident: b0210 article-title: Phase II study evaluating the association of gemcitabine, trastuzumab, and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) publication-title: J Clin Oncol – volume: 33 start-page: 3124 year: 2015 end-page: 3129 ident: b0455 article-title: Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma publication-title: J Clin Oncol – volume: 10 start-page: 345 year: 2005 end-page: 356 ident: b0245 article-title: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum publication-title: Oncologist – volume: 6 start-page: e1000097 year: 2009 ident: b0095 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med – volume: 19 start-page: 3396 year: 2013 end-page: 3403 ident: b0415 article-title: High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions publication-title: Clin Cancer Res – volume: 378 start-page: 731 year: 2018 end-page: 739 ident: b0290 article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children publication-title: N Engl J Med – volume: 8 start-page: 17945 year: 2017 end-page: 17959 ident: b0310 article-title: The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: a prospective cohort study publication-title: Oncotarget – volume: 29 start-page: 3037 year: 2011 end-page: 3043 ident: b0295 article-title: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression publication-title: J Clin Oncol – volume: 28 start-page: 3605 year: 2010 end-page: 3610 ident: b0235 article-title: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205 publication-title: J Clin Oncol – volume: 21 start-page: 730 year: 2015 end-page: 738 ident: b0155 article-title: A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors publication-title: Clin Cancer Res – volume: 23 start-page: iv5 year: 2012 ident: b0175 article-title: A phase 2 adjuvant trial of GI-4000 plus gemcitabine vs. Gemcitabine alone in ras+ patients with resected pancreas cancer: R1 subgroup analysis publication-title: Ann Oncol – volume: 4 year: 2018 ident: b0080 article-title: Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma publication-title: JAMA Oncol – volume: 30 start-page: 1094 year: 2013 end-page: 1100 ident: b0185 article-title: A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients publication-title: Oncol Rep – volume: 28 start-page: v409 year: 2017 end-page: v410 ident: b0170 article-title: An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer publication-title: Ann Oncol – volume: 144 start-page: 1316 year: 2013 end-page: 1326 ident: b0025 article-title: Therapeutic advances in pancreatic cancer publication-title: Gastroenterology – volume: 96 start-page: 448A year: 2016 end-page: 449A ident: b0275 article-title: A clinicopathologic study of ALK rearrangements in pancreatic ductal adenocarcinoma publication-title: Lab Invest – volume: 35 year: 2017 ident: b0360 article-title: Impact of BRCAness on the efficacy of oxaliplatin-based chemotherapy in patients with unresectable pancreatic cancer publication-title: J Clin Oncol – volume: 28 start-page: v249 year: 2017 ident: b0380 article-title: Prognosis of familial pancreatic cancer (FPC): a matched case analysis publication-title: Ann Oncol – volume: 111 start-page: 1132 year: 2014 end-page: 1138 ident: b0395 article-title: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers publication-title: Br J Cancer – volume: 24 start-page: 1150 year: 2016 end-page: 1158 ident: b0255 article-title: Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma publication-title: Mol Ther – reference: based on November 2017 SEER data submission, posted to the SEER web site, April 2018. – volume: 23 start-page: 6094 year: 2017 end-page: 6100 ident: b0355 article-title: Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype publication-title: Clin Cancer Res – volume: 128 start-page: 1120 year: 2011 end-page: 1128 ident: b0180 article-title: Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras publication-title: Int J Cancer – volume: 18 year: 2017 ident: b0215 article-title: Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis publication-title: Int J Mol Sci – reference: NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. 2018; Version 1; 2019. – volume: 22 start-page: 1430 year: 2004 end-page: 1438 ident: b0195 article-title: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer publication-title: J Clin Oncol – start-page: 35 year: 2017 ident: b0420 article-title: Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations publication-title: J Clin Oncol – volume: 372 start-page: 2509 year: 2015 end-page: 2520 ident: b9000 article-title: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency publication-title: N Engl J Med – volume: 89 start-page: 19 year: 2018 end-page: 26 ident: b0050 article-title: Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma publication-title: Eur J Cancer – volume: 124 start-page: 1374 year: 2018 end-page: 1382 ident: b0055 article-title: Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma publication-title: Cancer – year: 2014 ident: b0480 article-title: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy publication-title: Clin Cancer Res – volume: 7 start-page: ra107 year: 2014 ident: b0505 article-title: Resistance to dual blockade of the kinases PI3K and mTOR in <em>KRAS</em>-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR publication-title: Sci Signaling – volume: 24 start-page: 6204 year: 2018 end-page: 6211 ident: b0375 article-title: Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX publication-title: Clin Cancer Res – reference: Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. 2018;36:521. – volume: 212 start-page: 726 year: 2016 end-page: 734 ident: b0320 article-title: P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment publication-title: Pathol Res Pract – volume: 52 start-page: 12 year: 2017 end-page: 21 ident: b0435 article-title: Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review publication-title: Cancer Treat Rev – year: 2017 ident: b0265 article-title: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors publication-title: AACR annual meeting – volume: 30 start-page: 2391 year: 2012 end-page: 2399 ident: b0190 article-title: Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer publication-title: Invest New Drugs – volume: 15 start-page: 555 year: 2017 end-page: 562 ident: b0280 article-title: Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma publication-title: J Natl Compr Canc Netw – volume: 26 start-page: 784 year: 2008 end-page: 793 ident: b0220 article-title: Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation publication-title: Cancer Invest – volume: 69 start-page: S11 year: 2016 ident: b0260 article-title: A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors publication-title: Eur J Cancer – volume: 60 start-page: 32 year: 2017 end-page: 43 ident: b0065 article-title: Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies publication-title: Cancer Treat Rev – volume: 21 start-page: 4552 year: 2015 end-page: 4560 ident: b0440 article-title: Failures in phase III: causes and consequences publication-title: Clin Cancer Res – volume: 24 start-page: 902 year: 2018 end-page: 904 ident: b0495 article-title: A treatment strategy for KRAS-driven tumors publication-title: Nat Med – volume: 387 start-page: 545 year: 2016 end-page: 557 ident: b0035 article-title: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial publication-title: Lancet – volume: 30 start-page: 1216 year: 2012 end-page: 1223 ident: b0120 article-title: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy publication-title: Invest New Drugs – volume: 107 start-page: djv253 year: 2015 ident: b0445 article-title: Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval publication-title: J Natl Cancer Inst – volume: 24 start-page: 1344 year: 2018 end-page: 1354 ident: b0335 article-title: Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial publication-title: Clin Cancer Res – volume: 121 start-page: 4382 year: 2015 end-page: 4388 ident: b0460 article-title: Identification of germline genetic mutations in patients with pancreatic cancer publication-title: Cancer – reference: Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018. – volume: 28 start-page: v227 year: 2017 end-page: v228 ident: b0165 article-title: TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas publication-title: Ann Oncol – volume: 104 start-page: 240 year: 2016 end-page: 243 ident: b0100 article-title: De-duplication of database search results for systematic reviews in EndNote publication-title: J Med Libr Assoc JMLA – volume: 116 start-page: 697 year: 2017 end-page: 702 ident: b0390 article-title: Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer publication-title: Br J Cancer – volume: 6 start-page: 316 year: 2016 end-page: 329 ident: b0490 article-title: Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state publication-title: Cancer Discov – reference: Puleo F, Nicolle R, Blum Y, Cros J, Elarouci N, Franchimont D, et al. Clinical application and potential usefulness of targeted next-generation sequencing on resected pancreatic ductal adenocarcinoma; 2018. p. 78. – volume: 17 start-page: 251 year: 2015 end-page: 264 ident: b0350 article-title: Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology publication-title: J Mol Diagn – volume: 226 year: 2018 ident: b0400 article-title: BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma publication-title: J Am Coll Surg – volume: 21 start-page: 2029 year: 2015 end-page: 2037 ident: b0465 article-title: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial publication-title: Clin Cancer Res – volume: 535 start-page: 148 year: 2016 end-page: 152 ident: b0500 article-title: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases publication-title: Nature – volume: 369 start-page: 1691 year: 2013 end-page: 1703 ident: b0030 article-title: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine publication-title: N Engl J Med – volume: 12 year: 2017 ident: b0325 article-title: Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy publication-title: PLoS ONE – reference: Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185-203.e13. Doi: 10.1016/j.ccell.2017.07.007. – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: b0475 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N Engl J Med – reference: . – volume: 45 start-page: 1294 year: 2016 end-page: 1302 ident: b0345 article-title: miR-216b targets FGFR1 and confers sensitivity to radiotherapy in pancreatic ductal adenocarcinoma patients without EGFR or KRAS mutation publication-title: Pancreas – volume: 33 year: 2015 ident: b0140 article-title: Next-generation sequencing (NGS) to identify potential therapeutic targets in advanced pancreatic cancer publication-title: J Clin Oncol – volume: 6 start-page: 24560 year: 2015 end-page: 24570 ident: b0200 article-title: RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients publication-title: Oncotarget – year: 2018 ident: b0270 article-title: NRG1 Fusions in KRAS wild-type pancreatic cancer publication-title: Cancer Discov – start-page: 1 year: 2018 end-page: 15 ident: b0405 article-title: Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation publication-title: JCO Precision Oncology. – volume: 25 start-page: 1960 year: 2007 ident: 10.1016/j.ctrv.2019.03.003_b0085 article-title: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.9525 – volume: 21 start-page: 730 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0155 article-title: A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1814 – volume: 6 start-page: 18162 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0240 article-title: Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial publication-title: Oncotarget doi: 10.18632/oncotarget.4216 – volume: 6 start-page: 6744 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0470 article-title: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets publication-title: Nat Commun doi: 10.1038/ncomms7744 – volume: 69 start-page: S11 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0260 article-title: A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors publication-title: Eur J Cancer doi: 10.1016/S0959-8049(16)32624-7 – volume: 378 start-page: 731 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0290 article-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children publication-title: N Engl J Med doi: 10.1056/NEJMoa1714448 – volume: 30 start-page: 2391 year: 2012 ident: 10.1016/j.ctrv.2019.03.003_b0190 article-title: Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer publication-title: Invest New Drugs doi: 10.1007/s10637-012-9818-6 – volume: 60 start-page: 32 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0065 article-title: Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2017.08.007 – ident: 10.1016/j.ctrv.2019.03.003_b0450 doi: 10.1016/j.ccell.2017.07.007 – volume: 23 start-page: 6094 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0355 article-title: Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0899 – volume: 23 start-page: 2327 year: 2012 ident: 10.1016/j.ctrv.2019.03.003_b0300 article-title: Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma publication-title: Ann Oncol doi: 10.1093/annonc/mdr617 – volume: 28 start-page: v251 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0330 article-title: TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: results from the CONKO-001 study publication-title: Ann Oncol doi: 10.1093/annonc/mdx369.120 – volume: 15 start-page: 555 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0280 article-title: Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2017.0058 – volume: 28 start-page: v249 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0380 article-title: Prognosis of familial pancreatic cancer (FPC): a matched case analysis publication-title: Ann Oncol doi: 10.1093/annonc/mdx369.115 – volume: 22 start-page: 61 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0125 article-title: A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0979 – volume: 24 start-page: 902 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0495 article-title: A treatment strategy for KRAS-driven tumors publication-title: Nat Med doi: 10.1038/s41591-018-0111-x – volume: 369 start-page: 1691 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0030 article-title: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine publication-title: N Engl J Med doi: 10.1056/NEJMoa1304369 – volume: 45 start-page: 1294 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0345 article-title: miR-216b targets FGFR1 and confers sensitivity to radiotherapy in pancreatic ductal adenocarcinoma patients without EGFR or KRAS mutation publication-title: Pancreas doi: 10.1097/MPA.0000000000000640 – volume: 535 start-page: 148 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0500 article-title: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases publication-title: Nature doi: 10.1038/nature18621 – year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0265 article-title: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors – volume: 10 start-page: 345 year: 2005 ident: 10.1016/j.ctrv.2019.03.003_b0245 article-title: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum publication-title: Oncologist doi: 10.1634/theoncologist.10-5-345 – volume: 111 start-page: 1132 year: 2014 ident: 10.1016/j.ctrv.2019.03.003_b0395 article-title: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers publication-title: Br J Cancer doi: 10.1038/bjc.2014.418 – volume: 124 start-page: 1374 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0055 article-title: Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma publication-title: Cancer doi: 10.1002/cncr.31218 – volume: 24 start-page: 5018 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0340 article-title: Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-0531 – volume: 364 start-page: 1817 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0020 article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1011923 – volume: 16 start-page: 1397 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0410 article-title: An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions publication-title: Oncologist doi: 10.1634/theoncologist.2011-0185 – volume: 366 start-page: 2443 year: 2012 ident: 10.1016/j.ctrv.2019.03.003_b0475 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200690 – volume: 29 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0385 article-title: Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation publication-title: J Clin Oncol doi: 10.1200/jco.2011.29.4_suppl.268 – volume: 30 start-page: 1216 year: 2012 ident: 10.1016/j.ctrv.2019.03.003_b0120 article-title: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy publication-title: Invest New Drugs doi: 10.1007/s10637-011-9687-4 – volume: 26 start-page: 784 year: 2008 ident: 10.1016/j.ctrv.2019.03.003_b0220 article-title: Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation publication-title: Cancer Invest doi: 10.1080/07357900801918611 – volume: 17 start-page: 251 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0350 article-title: Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2014.12.006 – ident: 10.1016/j.ctrv.2019.03.003_b0045 doi: 10.1158/1538-7445.PANCA2014-B102 – volume: 24 start-page: 1150 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0255 article-title: Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma publication-title: Mol Ther doi: 10.1038/mt.2016.66 – volume: 81 start-page: 3 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0230 article-title: KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy publication-title: Oncology doi: 10.1159/000330194 – volume: 6 start-page: e1000097 year: 2009 ident: 10.1016/j.ctrv.2019.03.003_b0095 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 21 start-page: 4552 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0440 article-title: Failures in phase III: causes and consequences publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0124 – volume: 8 start-page: 17945 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0310 article-title: The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: a prospective cohort study publication-title: Oncotarget doi: 10.18632/oncotarget.14901 – volume: 372 start-page: 2509 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0425 article-title: PD-1 blockade in tumors with mismatch-repair deficiency publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 – volume: 12 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0325 article-title: Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy publication-title: PLoS ONE – volume: 50 start-page: 2072 year: 2014 ident: 10.1016/j.ctrv.2019.03.003_b0105 article-title: A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas publication-title: Eur J Cancer doi: 10.1016/j.ejca.2014.04.024 – volume: 24 start-page: 6204 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0375 article-title: Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-1472 – volume: 35 start-page: 792- year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0430 article-title: Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): a single institution experience publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.4_suppl.792 – volume: 7 start-page: ra107 year: 2014 ident: 10.1016/j.ctrv.2019.03.003_b0505 article-title: Resistance to dual blockade of the kinases PI3K and mTOR in <em>KRAS</em>-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR publication-title: Sci Signaling doi: 10.1126/scisignal.2005516 – volume: 29 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0225 article-title: Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma publication-title: J Clin Oncol – volume: 10 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0250 article-title: Phase II study of pelareorep (REOLYSIN((R))) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma publication-title: Cancers (Basel) doi: 10.3390/cancers10060160 – ident: 10.1016/j.ctrv.2019.03.003_b0070 doi: 10.1200/JCO.2019.37.4_suppl.188 – volume: 503 start-page: 548 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0485 article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature doi: 10.1038/nature12796 – volume: 16 start-page: 1324 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0135 article-title: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00188-6 – volume: 21 start-page: 2029 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0465 article-title: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0426 – volume: 387 start-page: 545 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0035 article-title: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)00986-1 – ident: 10.1016/j.ctrv.2019.03.003_b0285 doi: 10.1200/JCO.2018.36.4_suppl.521 – volume: 226 issue: 630–7 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0400 article-title: BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma publication-title: J Am Coll Surg – volume: 28 start-page: v409 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0170 article-title: An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdx376.018 – volume: 24 start-page: 1344 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0335 article-title: Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2994 – start-page: 35 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0420 article-title: Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations publication-title: J Clin Oncol – volume: 28 start-page: v227 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0165 article-title: TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas publication-title: Ann Oncol doi: 10.1093/annonc/mdx369.053 – volume: 372 start-page: 2509 issue: 26 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b9000 article-title: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 – volume: 518 start-page: 495 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0365 article-title: Whole genomes redefine the mutational landscape of pancreatic cancer publication-title: Nature doi: 10.1038/nature14169 – ident: 10.1016/j.ctrv.2019.03.003_b0005 – volume: 3 start-page: 516 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0130 article-title: Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.5383 – volume: 18 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0210 article-title: Phase II study evaluating the association of gemcitabine, trastuzumab, and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) publication-title: J Clin Oncol – volume: 19 start-page: 3396 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0415 article-title: High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3020 – volume: 33 start-page: 3124 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0455 article-title: Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2014.59.7401 – ident: 10.1016/j.ctrv.2019.03.003_b0510 – volume: 89 start-page: 19 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0050 article-title: Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.11.004 – volume: 23 start-page: iv5 year: 2012 ident: 10.1016/j.ctrv.2019.03.003_b0175 article-title: A phase 2 adjuvant trial of GI-4000 plus gemcitabine vs. Gemcitabine alone in ras+ patients with resected pancreas cancer: R1 subgroup analysis publication-title: Ann Oncol doi: 10.1016/S0923-7534(19)66467-7 – volume: 12 start-page: 97 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0115 article-title: Phase I/II study of refametinib (BAY 86–9766) in combination with gemcitabine in advanced pancreatic cancer publication-title: Target Oncol doi: 10.1007/s11523-016-0469-y – year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0270 article-title: NRG1 Fusions in KRAS wild-type pancreatic cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0036 – volume: 121 start-page: 4382 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0460 article-title: Identification of germline genetic mutations in patients with pancreatic cancer publication-title: Cancer doi: 10.1002/cncr.29664 – volume: 6 start-page: 24560 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0200 article-title: RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients publication-title: Oncotarget doi: 10.18632/oncotarget.4183 – volume: 96 start-page: 448A year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0275 article-title: A clinicopathologic study of ALK rearrangements in pancreatic ductal adenocarcinoma publication-title: Lab Invest – volume: 310 start-page: 1473 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0315 article-title: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the conko-001 randomized trial publication-title: JAMA doi: 10.1001/jama.2013.279201 – ident: 10.1016/j.ctrv.2019.03.003_b0040 – start-page: 1 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0405 article-title: Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation publication-title: JCO Precision Oncology. doi: 10.1200/PO.17.00316 – volume: 87 start-page: 458 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0305 article-title: Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2013.06.2039 – volume: 35 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0360 article-title: Impact of BRCAness on the efficacy of oxaliplatin-based chemotherapy in patients with unresectable pancreatic cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.4_suppl.250 – volume: 8 start-page: 44073 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0060 article-title: Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer publication-title: Oncotarget doi: 10.18632/oncotarget.17237 – volume: 18 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0215 article-title: Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis publication-title: Int J Mol Sci doi: 10.3390/ijms18050909 – volume: 104 start-page: 240 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0100 article-title: De-duplication of database search results for systematic reviews in EndNote publication-title: J Med Libr Assoc JMLA doi: 10.3163/1536-5050.104.3.014 – year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0160 article-title: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors – volume: 9 start-page: 19817 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0010 article-title: Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer publication-title: Oncotarget doi: 10.18632/oncotarget.24865 – volume: 30 start-page: 1094 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0185 article-title: A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients publication-title: Oncol Rep doi: 10.3892/or.2013.2556 – year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0110 article-title: Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer publication-title: Int J Cancer doi: 10.1002/ijc.31603 – volume: 116 start-page: 697 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0390 article-title: Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer publication-title: Br J Cancer doi: 10.1038/bjc.2017.19 – volume: 107 start-page: djv253 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0445 article-title: Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djv253 – volume: 4 year: 2018 ident: 10.1016/j.ctrv.2019.03.003_b0080 article-title: Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.3420 – volume: 13 start-page: 773 year: 2012 ident: 10.1016/j.ctrv.2019.03.003_b0145 article-title: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70270-X – volume: 28 start-page: 3605 year: 2010 ident: 10.1016/j.ctrv.2019.03.003_b0235 article-title: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.7550 – year: 2014 ident: 10.1016/j.ctrv.2019.03.003_b0480 article-title: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-3271 – volume: 212 start-page: 726 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0320 article-title: P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment publication-title: Pathol Res Pract doi: 10.1016/j.prp.2016.06.001 – volume: 10 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0150 article-title: pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.TARG-11-A88 – volume: 26 start-page: 1923 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0205 article-title: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdv264 – volume: 26 start-page: 224 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0370 article-title: Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000178 – volume: 52 start-page: 12 year: 2017 ident: 10.1016/j.ctrv.2019.03.003_b0435 article-title: Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2016.10.009 – volume: 144 start-page: 1316 year: 2013 ident: 10.1016/j.ctrv.2019.03.003_b0025 article-title: Therapeutic advances in pancreatic cancer publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.01.078 – volume: 128 start-page: 1120 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0180 article-title: Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras publication-title: Int J Cancer doi: 10.1002/ijc.25449 – volume: 74 start-page: 2913 year: 2014 ident: 10.1016/j.ctrv.2019.03.003_b0015 article-title: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-0155 – volume: 29 start-page: 3037 year: 2011 ident: 10.1016/j.ctrv.2019.03.003_b0295 article-title: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression publication-title: J Clin Oncol doi: 10.1200/JCO.2010.33.8038 – ident: 10.1016/j.ctrv.2019.03.003_b0075 doi: 10.1158/1538-7445.AM2018-4603 – volume: 22 start-page: 1430 year: 2004 ident: 10.1016/j.ctrv.2019.03.003_b0195 article-title: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2004.10.112 – volume: 6 start-page: 316 year: 2016 ident: 10.1016/j.ctrv.2019.03.003_b0490 article-title: Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-1105 – volume: 33 year: 2015 ident: 10.1016/j.ctrv.2019.03.003_b0140 article-title: Next-generation sequencing (NGS) to identify potential therapeutic targets in advanced pancreatic cancer publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.3_suppl.357 |
| SSID | ssj0009369 |
| Score | 2.4203796 |
| SecondaryResourceType | review_article |
| Snippet | •Genomic alterations in PDAC represent potential targeting opportunities to individualize therapy.•Attempts to target key somatic driver mutations in PDAC have... Pancreatic cancer (PDAC) is one of the most challenging cancers to treat with modest recent improvements in survival from new systemic therapies. There is... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 27 |
| SubjectTerms | Animals Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics DNA damage repair DNA Repair - drug effects DNA Repair - genetics Genomic alteration (GA) Genomics - methods Germline mutation Humans Microsatellite instability Mismatch repair (MMR) Pancreatic ductal adenocarcinoma (PDAC) Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Somatic mutation |
| Title | Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0305737219300519 https://dx.doi.org/10.1016/j.ctrv.2019.03.003 https://www.ncbi.nlm.nih.gov/pubmed/30927677 https://www.proquest.com/docview/2200768804 https://pubmed.ncbi.nlm.nih.gov/PMC6504563 |
| Volume | 75 |
| WOSCitedRecordID | wos000467510600004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1532-1967 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009369 issn: 0305-7372 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfKZTISb1GqJG5ih7cKDcbEJgRjKk-Razu0U5VOadrtZ_ETOY4dJ13FuEi8RFVqN1bPF59j-3zfQei1SiLGZaR8JmNNyWFDn6eE-3EOvkxMyETUW9lnH-nJCRuP00-93o-GC7Oe06JgV1fpxX81NdwDY2vq7F-Y2_0o3IDPYHS4gtnh-keGf69qprFnqnFbygq88yY8FJ4WeNUCATDhgB8rxQyac6PZqlVWp5dcB6Q6mXbpGXaWpgY2tC1L2zSEdk1p0Q8o2wOGVvRAqLKTxm5VT92GDnSbGmJ_tfI-D1wa0GIum4yzo8WUF4VzG2e8_D5Vpg6kln32jl2vb6sOxcg7HHS3MjR7Ku5uZTiOTZvQVPO6oJUupmM8VjNNRz7MHbQ7j9O4OxHTjks3-jFbzsLsW5wPRFWudZKflbslrWt0CYtf9Cj0ICDeraPeHbQX0TiFeXRv9OFgfNQKPZO6jKIbtSVqmZzC60_6VTC0vdi5nrPbCYJO76G7dvWCRwZ191FPFQ_Q7WObn_EQXVrwYQc-PCtwCz5swIc3wYcBfJhjCz5swYct-PAW-N7gEbbQwwZXj9DXdwenbw99W9rDFzGNKj9VkoaEByrlKcSYeTKchCJUYSRUwgSNSCJDohLKheKEcoiCcyLimKdUKCbBDT1Gu8WiUE8RTnNGuARTKBYPJQ-5DMNJHkwCkUtJWdhHYfMfZ8Lq3uvyK_OsSXA8z7RdMm2XLCBaLbePPNfnwqi-3NiaNKbLGj4zeOAMcHZjr9j1stGuiWJ_2-9Vg44MXIE-3-OFWqyWWRTV5-osGPbRE4MWN3oSpBFNKO0juoEj10DLzG9-U8ymtdw8rOFglUWe_eN4n6M77bv-Au1W5Uq9RLfEupoty320Q8ds375EPwFMHv6B |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genomic+profiling+in+pancreatic+ductal+adenocarcinoma+and+a+pathway+towards+therapy+individualization%3A+A+scoping+review&rft.jtitle=Cancer+treatment+reviews&rft.au=Singh%2C+Ritu+R.&rft.au=Goldberg%2C+Johanna&rft.au=Varghese%2C+Anna+M.&rft.au=Yu%2C+Kenneth+H.&rft.date=2019-05-01&rft.pub=Elsevier+Ltd&rft.issn=0305-7372&rft.eissn=1532-1967&rft.volume=75&rft.spage=27&rft.epage=38&rft_id=info:doi/10.1016%2Fj.ctrv.2019.03.003&rft.externalDocID=S0305737219300519 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7372&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7372&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7372&client=summon |